Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin
The provisional patent application covers, among other things, an enhancer that reduces the enzymatic breakdown of psilocin, the active ingredient in psilocybin that causes psychedelic effects.
- The provisional patent application covers, among other things, an enhancer that reduces the enzymatic breakdown of psilocin, the active ingredient in psilocybin that causes psychedelic effects.
- NeuroPharm is a developer of natural health, psilocybin-based treatments for PTSD and mental health disorders in the veteran community.
- Josh Bartch, CEO of Mydecine, commented: The invention covered by this exciting provisional patent filing holds great promise for the treatment of a range of psychiatric disorders.
- For further information about Mydecine Innovations Group Inc., please consult the Company's profile on SEDAR at www.sedar.com or visit the Company's website at http://mydecine.com/.